Ventio

VENTIO is an innovative startup specialized in digital health, in particular in the processing of sensitive data from biomedical imaging. The company launches it secured cloud services Ventio-cloud by providing an innovative brain imaging biomarker sensitive to iron with the QSMetric – research edition software.

QSMetric implements the Quantitative Susceptibility Mapping (QSM) technology, patented and FDA-cleared. Discovered and published by its founder and the subject of more than 3000 scientific publications, Ventio is the exclusive distributor in Europe for research applications in SaaS mode.

Quantitative Susceptibility Mapping (QSM) must be included in the brain MRI protocols of your clinical trials and cohort studies. It is capable of providing 3D localization and quantification of magnetic susceptbility linked to iron in the human brain, and involved in neurodegenerative, neuroinflammatory and neurovascular diseases.

We provide associated services for a one stop shop: from QSM imaging protocol installation and quality control to case review.

Ventio received the 1st price for innovation in medical imaging in 2022 of the French Radiology Society, the SNITEM, Medicen and the French Healthcare association. Leverage on the only provider that builds upon more than 15 years of experience in QSM processing.